← Leaderboards
James E Zadina
Southeast Louisiana Veterans Health Care
$1,792,730
Attributed
$3,344,010
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $3.1M · FY2013–25$5M$3.8M$2.5M$1.3M$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,344,010 · 2
VA$0 · 3
By mechanism
UG3$3,102,560 · 1
U18$241,450 · 1
I01$0 · 3
Top collaborators
- Michael William Lark1 shared
Others in their field
Top investigators on “Rewards”
- S. Claiborne Johnston · University Of California San Francisco$83,501,485
- Bruce R. Blazar · University Of Minnesota$67,782,274
- Adrian Hernandez · Duke University$50,769,596
- Muredach P Reilly · Columbia University Health Sciences$46,763,273
- Jennifer R Grandis · University Of Pittsburgh At Pittsburgh$44,486,622
- Karl Alexander Deisseroth · Stanford University$39,838,805
Research focus
RewardsPharmaceutical PreparationsPainAnalogRattusPain ManagementOpioidAnalgesicsMorphineBrainVentilatory DepressionLeadChronicAdverse EffectsVeteransMu Opioid ReceptorsAgonistLaboratoriesSide EffectPropertyDoseMotor ImpairmentAbsence Of Pain SensationOpioid Epidemic
Grant awards (13)
Development of Glycosylated Endomorphin Analogs with Low Abuse Liability for Treatment of Pain.$0
I01 · FY2025 · VA · contact PI
Development of Glycosylated Endomorphin Analogs with Low Abuse Liability for Treatment of Pain.$0
I01 · FY2024 · VA · contact PI
A Novel Analgesic with Reduced Side Effects and Abuse Liability Relative to Morphine, With Potential for Opioid Dependence Therapy$0
I01 · FY2022 · VA · contact PI
Glycosylated Endomorphin Analogs for Treatment of Opioid Use Disorder (OUD)$241,450
U18 · FY2021 · DA · contact PI
A Novel Analgesic with Reduced Side Effects and Abuse Liability Relative to Morphine, With Potential for Opioid Dependence Therapy$0
I01 · FY2021 · VA · contact PI
A Novel Analgesic with Reduced Side Effects and Abuse Liability Relative to Morphine, With Potential for Opioid Dependence Therapy$0
I01 · FY2020 · VA · contact PI
Development of a safe and effective novel mechanism analgesic to treat moderate to severe pain with low or absent abuse liability.$3,102,560
UG3 · FY2019 · DA
A Novel Analgesic with Reduced Side Effects and Abuse Liability Relative to Morphine, With Potential for Opioid Dependence Therapy$0
I01 · FY2019 · VA · contact PI
A Novel Analgesic with Reduced Side Effects and Abuse Liability Relative to Morphine, With Potential for Opioid Dependence Therapy$0
I01 · FY2018 · VA · contact PI
Novel Analgesics for Improved Pain Therapy in Advancing Age$0
I01 · FY2016 · VA · contact PI
Novel Analgesics for Improved Pain Therapy in Advancing Age$0
I01 · FY2015 · VA · contact PI
Novel Analgesics for Improved Pain Therapy in Advancing Age$0
I01 · FY2014 · VA · contact PI
Novel Analgesics for Improved Pain Therapy in Advancing Age$0
I01 · FY2013 · VA · contact PI